Edaravone is a free radical scavenger that is currently used in Asia for the treatment of stroke and Amyotrophic Lateral Sclerosis (ALS) and in the United States for the treatment of ALS. Edaravone is currently only available as an intravenous formulation (IV), given daily as 1-hour infusions, interrupted by treatment holidays to lower patient burden. Daily IV infusions are generally considered incompatible with (sub-)chronic indications such as ALS and Alzheimer’s Disease. Treeway developed an oral formulation of edaravone (TW001) to overcome the challenges related to intravenously administered edaravone.It is hypothesized that an antioxidant therapy, such as edaravone, might also be a promising treatment strategy for Alzheimer’s Disease (AD) as oxidative stress plays an important role in the development and progression of the disease. Current treatment options for AD however, do not target oxidative stress. In light of this, Treeway plans to perform a Phase II study to evaluate the safety, pharmacodynamics and pharmacokinetics of TW001 in Alzheimer patients. TW001 has the potential to slow down AD disease progression, thus improving the patient’s quality of life. In the long term, TW001 has the potential to be used in a combination therapy with the aim to completely halt disease progression. AD is a complex disease in which a multitude of different processes play a role in disease onset and progression. A combination therapy could modify the course of the disease by targeting several of these different processes. Treeway believes that both in the short term and in the long term TW001 can have a positive effect on the quality of life of Alzheimer patients.